The store will not work correctly when cookies are disabled.
5-(6-Methoxy-1H-indol-3-yl)-3-(pyridin-4-yl)-4,5-dihydroisoxazole
ID: ALA4244687
PubChem CID: 145985275
Max Phase: Preclinical
Molecular Formula: C17H15N3O2
Molecular Weight: 293.33
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: COc1ccc2c(C3CC(c4ccncc4)=NO3)c[nH]c2c1
Standard InChI: InChI=1S/C17H15N3O2/c1-21-12-2-3-13-14(10-19-16(13)8-12)17-9-15(20-22-17)11-4-6-18-7-5-11/h2-8,10,17,19H,9H2,1H3
Standard InChI Key: DKLBKXQWZHGSHV-UHFFFAOYSA-N
Molfile:
RDKit 2D
22 25 0 0 0 0 0 0 0 0999 V2000
2.4006 -12.3362 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3995 -13.1558 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1075 -13.5647 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1057 -11.9274 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8144 -12.3326 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8146 -13.1558 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5976 -13.4100 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.0813 -12.7438 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5972 -12.0781 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.9981 -11.3664 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.8191 -11.3885 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0923 -10.6187 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.4446 -10.1209 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.7712 -10.5832 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.9090 -10.6152 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3184 -11.3231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.1343 -11.3200 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.5405 -10.6105 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.1248 -9.9027 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3103 -9.9092 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6915 -13.5638 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.9841 -13.1547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 2 0
9 5 1 0
9 10 1 0
10 11 1 0
11 12 1 0
12 13 2 0
13 14 1 0
14 10 1 0
12 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 15 1 0
2 21 1 0
21 22 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 293.33 | Molecular Weight (Monoisotopic): 293.1164 | AlogP: 3.44 | #Rotatable Bonds: 3 |
Polar Surface Area: 59.50 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 3.86 | CX LogP: 2.36 | CX LogD: 2.36 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.80 | Np Likeness Score: -0.47 |
References
1. Chaitanya MVSK, Reddy POV, Nikhil K, Kumar A, Shah K, Kumar D.. (2018) Synthesis and anticancer activity studies of indolylisoxazoline analogues., 28 (17): [PMID:30072225] [10.1016/j.bmcl.2018.07.035] |